Lisa H. Butterfield

Lisa H. Butterfield

Auto-generated profile, based on publicly available information

Lisa H. Butterfield

Parker Institute for Cancer Immunotherapy, San Francisco, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HOHideho Okada
Hideho Okada
PKPawel Kalinski
Pawel Kalinski
RURyo Ueda
Ryo Ueda
AHAki Hoji
Aki Hoji
Gary KohanbashGary Kohanbash
Gary Kohanbash
FLFrank S. Lieberman
Frank S. Lieberman
Purpose: A phase I/II trial was performed to evaluate the safety and immunogenicity of a novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides for glioma-associated antigen (GAA) epitopes and administration of polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in HLA-A2+patients with recurrent malignant gliomas. GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100.Patients and Methods: Twenty-two patients (13 with glioblastoma multiforme [GBM], five with anaplastic astrocytoma [AA], three with anaplastic oligodendroglioma [AO], and one with anaplastic oligoastrocytoma [AOA]) received at least one vaccination, and 19 patients received at least four vaccinations at two αDC1 dose levels (1 × or 3 × 107/dose) at 2-week intervals intranodally. Patients also received twice weekly intramuscular injections of 20 μg/kg poly-ICLC. Patients who demonstrated positive radiologic response or stable disease without major adverse events were allowed to receive booster vaccines. T-lymphocyte responses against GAA epitopes were assessed by enzyme-linked immunosorbent spot and HLA-tetramer assays.Results: The regimen was well-tolerated. The first four vaccines induced positive immune responses against at least one of the vaccination-targeted GAAs in peripheral blood mononuclear cells in 58% of patients. Peripheral blood samples demonstrated significant upregulation of type 1 cytokines and chemokines, including interferon-α and CXCL10. Nine (four GBM, two AA, two AO, and one AOA) achieved progression-free status lasting at least 12 months. One patient with recurrent GBM demonstrated sustained complete response. IL-12 production levels by αDC1 positively correlated with time to progression.Conclusion: These data support safety, immunogenicity, and preliminary clinical activity of poly-ICLC-boosted αDC1-based vaccines.

3 June 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LPLacey J. Padrón
Lacey J. Padrón
DMDeena M. Maurer
Deena M. Maurer
MOMark H. O’hAra
Mark H. O’hAra
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
RWRobert A. Wolff
Robert A. Wolff
RVRobert H. Vonderheide
Robert H. Vonderheide
Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-line metastatic PDAC (NCT03214250). In 105 patients analyzed for efficacy, the primary endpoint of 1-year overall survival (OS) was met for nivo/chemo (57.7%, P = 0.006 compared to historical 1-year OS of 35%, n = 34) but was not met for sotiga/chemo (48.1%, P = 0.062, n = 36) or sotiga/nivo/chemo (41.3%, P = 0.223, n = 35). Secondary endpoints were progression-free survival, objective response rate, disease control rate, duration of response and safety. Treatment-related adverse event rates were similar across arms. Multi-omic circulating and tumor biomarker analyses identified distinct immune signatures associated with survival for nivo/chemo and sotiga/chemo. Survival after nivo/chemo correlated with a less suppressive tumor microenvironment and higher numbers of activated, antigen-experienced circulating T cells at baseline. Survival after sotiga/chemo correlated with greater intratumoral CD4 T cell infiltration and circulating differentiated CD4 T cells and antigen-presenting cells. A patient subset benefitting from sotiga/nivo/chemo was not identified. Collectively, these analyses suggest potential treatment-specific correlates of efficacy and may enable biomarker-selected patient populations in subsequent PDAC chemoimmunotherapy trials.

15 September 2015 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ATAhmad Tarhini
Ahmad Tarhini
HZHaris Zahoor
Haris Zahoor
YLYan Lin
Yan Lin
UMUsha Malhotra
Usha Malhotra
CSCindy Sander
Cindy Sander
John M. KirkwoodJohn M. Kirkwood
John M. Kirkwood
Background Within-household transmission of COVID-19 is responsible for a significant number of infections. The risk of within-household infection is greatly increased among those from Black Asian and minority ethnic (BAME) and low income communities. Efforts to protect these communities are urgently needed. The aim of this study is to explore the acceptability of the availability of accommodation to support isolation among at risk populations. Methods Our study used a mixed methods design structured in two phases. In phase 1, we conducted a survey study of a sample of volunteers from our existing database of 300 individuals who had provided consent to be contacted about ongoing research projects into infection control. In phase 2, we conducted semi-structured interviews with 19 participants from BAME communities and low income communities recruited through social media. Results Participants from the survey and interview phase of the study viewed the provision of accommodation as important and necessary. Factors influencing likely uptake of accommodation included perceived 1) vulnerability of household 2) exposure to the virus and 3) options for isolation at home. Barriers to accepting the offer of accommodation included 1) being able to isolate at home 2) wanting to be with family 3) caring responsibilities 4) concerns about mental wellbeing 5) upheaval of moving when ill and 6) concerns about infection control. Participants raised a series of issues that should be addressed before accommodation is offered. These included questions regarding who should use temporary accommodation and at what stage to effectively reduce transmission in the home, and how infection control in temporary accommodation would be managed. Conclusion This research provides evidence that the provision of accommodation to prevent within household transmission of the virus is viewed as acceptable, feasible and necessary by many people who are concerned about infection transmission in the home. We explore ways in which accommodation might be offered. In particular, vulnerable members of the household could be protected if accommodation is offered to individuals who are informed through test trace and isolate that they have been in contact with the virus.

10 May 2012 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
John M. KirkwoodJohn M. Kirkwood
John M. Kirkwood
LBLisa H. Butterfield
Lisa H. Butterfield
ATAhmad A. Tarhini
Ahmad A. Tarhini
HZHassane Zarour
Hassane Zarour
PKPawel Kalinski
Pawel Kalinski
SFSoldano Ferrone
Soldano Ferrone
The immunotherapy of cancer has made significant strides in the past few years due to improved understanding of the underlying principles of tumor biology and immunology. These principles have been critical in the development of immunotherapy in the laboratory and in the implementation of immunotherapy in the clinic. This improved understanding of immunotherapy, enhanced by increased insights into the mechanism of tumor immune response and its evasion by tumors, now permits manipulation of this interaction and elucidates the therapeutic role of immunity in cancer. Also important, this improved understanding of immunotherapy and the mechanisms underlying immunity in cancer has fueled an expanding array of new therapeutic agents for a variety of cancers. Pegylated interferon‐α2b as an adjuvant therapy and ipilimumab as therapy for advanced disease, both of which were approved by the United States Food and Drug Administration for melanoma in March 2011, are 2 prime examples of how an increased understanding of the principles of tumor biology and immunology have been translated successfully from the laboratory to the clinical setting. Principles that guide the development and application of immunotherapy include antibodies, cytokines, vaccines, and cellular therapies. The identification and further elucidation of the role of immunotherapy in different tumor types, and the development of strategies for combining immunotherapy with cytotoxic and molecularly targeted agents for future multimodal therapy for cancer will enable even greater progress and ultimately lead to improved outcomes for patients receiving cancer immunotherapy. CA Cancer J Clin 2012. © 2012 American Cancer Society.

6 December 2023 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
LBLisa H. Butterfield
Lisa H. Butterfield
YNYana G. Najjar
Yana G. Najjar

15 January 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
PSPatricia M. Santos
Patricia M. Santos
LBLisa H. Butterfield
Lisa H. Butterfield
Dendritic cells (DC) are specialized immune cells that play a critical role in promoting an immune response against Ags, which can include foreign pathogenic Ags and self-tumor Ags. DC are capable of boosting a memory T cell response but most importantly they are effective initiators of naive T cell responses. Many years of studies have focused on the use of DC vaccines against cancer to initiate and shape an antitumor-specific immune response and/or boost existing spontaneous antitumor T cell responses. In this study we give a brief overview of DC biology, function, and cellular subsets, and review the current status of the field of DC as cancer vaccines.